Kidney Function and Cognitive Health in Older Adults: The Cardiovascular Health Study

Brendan Darsie*, Michael G. Shlipak, Mark J. Sarnak, Ronit Katz, Annette L. Fitzpatrick, and Michelle C. Odden

* Correspondence to Brendan Darsie, Oregon State University, 141B Milam Hall, Corvallis, OR 97331 (e-mail: brendan.darsie@gmail.com).

Initially submitted September 25, 2013; accepted for publication April 3, 2014.

Recent evidence has demonstrated the importance of kidney function in healthy aging. We examined the association between kidney function and change in cognitive function in 3,907 participants in the Cardiovascular Health Study who were recruited from 4 US communities and studied from 1992 to 1999. Kidney function was measured by cystatin C–based estimated glomerular filtration rate (eGFRcys). Cognitive function was assessed using the Modified Mini-Mental State Examination and the Digit Symbol Substitution Test, which were administered up to 7 times during annual visits. There was an association between eGFRcys and change in cognitive function after adjustment for confounders; persons with an eGFRcys of less than 60 mL/minute/1.73 m² had a 0.64 (95% confidence interval: 0.51, 0.77) points/year faster decline in Modified Mini-Mental State Examination score and a 0.42 (95% confidence interval: 0.28, 0.56) points/year faster decline in Digit Symbol Substitution Test score compared with persons with an eGFRcys of 90 or more mL/minute/1.73 m². Additional adjustment for intermediate cardiovascular events modestly affected these associations. Participants with an eGFRcys of less than 60 mL/minute/1.73 m² had fewer cognitive impairment–free life-years on average compared with those with eGFRcys of 90 or more mL/minute/1.73 m², independent of confounders and mediating cardiovascular events (mean difference = −0.44, 95% confidence interval: −0.62, −0.26). Older adults with lower kidney function are at higher risk of worsening cognitive function.

Abbreviations: 3MS, Modified Mini-Mental State; APOE, apolipoprotein E; CHS, Cardiovascular Health Study; CI, confidence interval; CIFLY, cognitive impairment–free life-year; DSST, Digital Symbol Substitution Test; eGFRcreatinine, creatinine-based estimated glomerular filtration rate; eGFRcys, cystatin C–based estimated glomerular filtration rate.

Recent evidence has demonstrated the importance of kidney function in healthy aging (1). Reduced kidney function is associated with cardiovascular outcomes, frailty, and other adverse health outcomes (2–5). There is evidence from cross-sectional studies that poor kidney function is associated with cognitive impairment (6, 7), as well as evidence from longitudinal studies that poor kidney function is associated with declines in cognitive function (8–17). Cognitive impairment is a disability that has severely limiting effects on quality of life and life expectancy, and it precedes the onset of dementia (18). Previous studies have used many different measures of cognitive function, some over several waves of follow-up (8, 9, 16); however, the majority of studies used serum creatinine as the marker of kidney function (6–15). Creatinine measurements can be limited in the setting of aging because of the dual influence of kidney function and muscle mass on serum creatinine concentrations; persons with low muscle mass may have normal or low concentrations of creatinine despite the presence of reduced kidney function. Cystatin C is an alternative measure of kidney function that is not associated with muscle mass and may be a more accurate measure in the elderly population (19, 20).

Few studies have used cystatin C to evaluate the association between kidney function and cognitive outcomes. One study in the Health, Aging, and Body Composition cohort found a significant association between serum concentrations...
of cystatin C and cognitive function in elderly participants (21). A publication from the Cardiovascular Health Study (CHS) showed an association between cystatin C and an outcome described as “successful aging,” which was defined as remaining free of 3 major classes of disease (i.e., incident cancer, cardiovascular disease, and chronic obstructive pulmonary disease) and without a persistent physical disability or cognitive impairment (1). Another report from the Uppsala Longitudinal Study found an association between cystatin C and Alzheimer’s disease in a cohort of elderly men (22).

A recent review of studies investigating the association between kidney function and cognitive function recognized the need for more studies using multiple tests of cognitive function and measures of cognition that are relevant to patients (16). The current study extends the prior literature by evaluating associations of estimated glomerular filtration rate measured by cystatin C and cognitive function measured by 2 different test batteries over 6 years of follow-up in the CHS. In addition, we explored intermediate clinical cardiovascular events as potential mediating factors. Finally, although kidney function and cognitive function are both associated with an increased risk of death, prior analyses have not accounted for this competing risk. By evaluating kidney function with an outcome of cognitive impairment–free life-years (CIFLYs), we more thoroughly describe this association using an outcome that 1) is meaningful to older adults and 2) accounts for the dual impact of kidney dysfunction on cognitive impairment and death. We hypothesized that baseline cystatin C–based kidney function would be associated with a decline in cognitive function and CIFLYs, and that these associations would be mediated by clinical cardiovascular disease.

**METHODS**

**Study population**

The Cardiovascular Health Study (CHS) is a community-based study of adults aged 65 years and older at baseline. The primary aim of the CHS is to evaluate risk factors for the development and progression of cardiovascular disease in the elderly (23). The study recruited persons from Medicare eligibility lists in Forsyth County, North Carolina; Sacramento County, California; Washington County, Maryland; and Pittsburgh, Pennsylvania, in 1989–1990. Black participants were actively recruited during a supplemental enrollment process of the CHS during 1992–1993; they comprise 15% of CHS participants. The eligibility criteria were as follows: 1) age 65 years or older; 2) not institutionalized; 3) expected to remain in the current community for 3 years or longer; 4) not undergoing active treatment for cancer; and 5) provided informed consent without requiring a proxy respondent. The 1992–1993 visit is used as the baseline for the present study in order to have the same baseline year for the initial and supplemental cohorts.

Participants completed study visits at enrollment and annually through 1998–1999. During these visits, researchers conducted interviews and physical examinations, administered health questionnaires, and collected blood specimens. Hospital discharge summaries and International Classification of Diseases, Ninth Revision, codes were collected for all hospitalizations during the follow-up period. The study was approved by institutional review boards at each site, and informed consent was obtained from all participants.

**Cognitive function**

Cognitive function was measured annually during in-person visits from 1990 to 1999 using the Modified Mini-Mental State (3MS) Examination and the Digit Symbol Substitution Test (DSST). The 3MS Examination is a measure of global cognition with possible scores ranging from 0 to 100, and the DSST is a measure of executive cognitive abilities and processing speed with scores ranging from 0 to 90 (24, 25). There was substantial missingness for both 3MS Examination and DSST scores in this study. Of 25,920 potential person-visits, 15% were missing 3MS Examination scores, and 19% were missing DSST scores. Beginning in 1996, participants who did not attend the in-person visit were contacted by telephone and asked to complete the Telephone Interview for Cognitive Status, a brief interview designed to identify cognitive impairment in patients with Alzheimer’s disease. The Telephone Interview for Cognitive Status was used to impute missing 3MS Examination data by using the method of Arnold et al. (26). Additionally, missing 3MS Examination values were imputed by carrying nonmissing values from previous years forward 1 year and nonmissing values from later years backward 1 year. After these imputations, only 5% of the person-visits were missing 3MS Examination scores. We did not impute DSST scores because there was no CHS-validated conversion of the Telephone Interview for Cognitive Status to the DSST. We considered 3MS Examination score to be the primary outcome of interest because of the missingness in the DSST scores and because the 3MS Examination is more commonly used in epidemiologic and clinical studies. Incident cognitive impairment was defined as a score of less than 80 on the 3MS Examination during 2 consecutive visits, a score of less than 80 on the 3MS Examination and then a missing score on the next visit, or missing 3MS Examination scores for 4 consecutive years (i.e., 2 consecutive missing values after the imputation procedure described above) (27). We created the following new outcome as an additional analysis: CIFLYs, which is the time a person remains alive and free of cognitive impairment. This measure counts the number of years a person remains alive and not cognitively impaired and ranges from 0 to 6 years.

**Kidney function**

Kidney function was measured by serum cystatin C, a measure that may better estimate glomerular filtration rate in the elderly than serum creatinine (19, 20). Assays were performed in serum specimens obtained from fasting participants. Specimens had been stored at −70°C. Serum cystatin C was measured by a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Dade Behring, Inc., Deerfield, Illinois) with a nephelometer (BN II, Dade Behring, Inc.) (28). The assay remained stable, with no change in the values measured, over 5 cycles of freezing and thawing. The assay range was 0.195–7.330 mg/L. The interassay coefficient of
variation ranged from 2.3% to 3.1%, and the intraassay coefficient of variation ranged from 2.0% to 2.8%. Cystatin C–based estimated glomerular filtration rate (eGFR\text{cys}) was calculated on the basis of the Chronic Kidney Disease Epidemiology Collaboration equation \((133 \times (\text{serum cystatin C} / 0.8)^{-0.399} \times 0.996 \times \text{age} \times 0.932 \text{if female})\) for serum cystatin C \(\geq 0.8\, \text{mg/L}; 133 \times (\text{serum cystatin C} / 0.8)^{-1.328} \times 0.996 \times \text{age} \times 0.932 \text{if female})\) for serum cystatin C \(< 0.8\, \text{mg/L})\) (29).

Prior research has demonstrated that serum creatinine age \((\times 0.932 \text{if female})\) for ascertainment of death status.

We achieved 100% complete follow-up of 3,907 participants in our sample, 778 \((20\%)\) had eGFR\text{cys} of less than 60; 2,415 \((62\%)\) had eGFR\text{cys} of 60–89.9; and 714 \((18\%)\) had eGFR\text{cys} of 90 or more (Table 1). On average, participants with higher eGFR\text{cys} tended to be younger, were more likely to be female, and were more likely to self-report nonwhite race. The participants with higher eGFR\text{cys} also tended to have a higher level of education, were more likely to have never smoked, had lower body mass index values and systolic blood pressure, and had higher diastolic blood pressure. Additionally, participants with higher eGFR\text{cys} were less likely to have hypertension, had lower average C-reactive protein levels, were more likely to have depressive symptoms, and more likely to be carriers of the APOE 4 allele, and had higher average scores on the 3MS Examination and DSST. The average length of follow-up was 5.3 years.

At baseline, eGFR\text{cys} was associated with 3MS Examination score; persons with eGFR\text{cys} of less than 60 had lower 3MS Examination scores compared with participants with eGFR\text{cys} of 90 or more. This cross-sectional association no
longer reached statistical significance after adjustment for confounders (Table 2). Additionally, there were no statistically significant differences in mean 3MS Examination score for those with eGFR_{cys} of 90 or more compared with those with eGFR_{cys} of 60–89.9. The results were similar when we examined DSST score as the outcome. There was a statistically significant cross-sectional association between eGFR_{cys} and 3MS Examination score at baseline; unlike the results for 3MS Examination scores, the association among persons with eGFR_{cys} of less than 60 compared with those with eGFR_{cys} of 90 or more remained significant despite adjustment for confounders.

There was a highly significant association between baseline eGFR_{cys} and longitudinal change in 3MS Examination score over the 6 years of follow-up, and this association persisted even after adjustment for confounders and hypothesized mediators. Both those with eGFR_{cys} of less than 60 and those with eGFR_{cys} of 60–89.9 had significantly faster declines in 3MS Examination scores compared with those with eGFR_{cys} of 90 or more over the study period (Table 3). Participants with lower eGFR_{cys} had a steeper decline in predicted 3MS Examination score over time (Figure 1). There was a longitudinal association between eGFR_{cys} and DSST score (Table 3); there was a steeper decrease in DSST score over the study period among participants with lower eGFR_{cys} compared to those with higher eGFR_{cys}, even after adjustment for potential confounders and hypothesized mediators.

### Table 1. Baseline Characteristics of Participants Stratified by Baseline Kidney Function Measured by eGFR_{cys}, Cardiovascular Health Study, 1992–1993

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Subjects With eGFR_{cys} &lt;60* (n = 778)</th>
<th>Subjects With eGFR_{cys} 60–89.9* (n = 2,415)</th>
<th>Subjects With eGFR_{cys} ≥90** (n = 714)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)c No. %</td>
<td>Mean (SD)c No. %</td>
<td>Mean (SD) No. %</td>
</tr>
<tr>
<td>Age, years</td>
<td>77.5 (5.9)*** 743 (4.7)***</td>
<td>72.7 (4.2)</td>
<td></td>
</tr>
<tr>
<td>Female sex</td>
<td>437 56.2*** 1,451 60.1***</td>
<td>506 70.9</td>
<td></td>
</tr>
<tr>
<td>Nonwhite race</td>
<td>104 13.4*** 374 15.5***</td>
<td>214 30.0</td>
<td></td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than high school</td>
<td>236 30.4*** 587 24.3</td>
<td>171 24.0</td>
<td></td>
</tr>
<tr>
<td>High school or GED</td>
<td>217 27.9</td>
<td>713 29.6</td>
<td></td>
</tr>
<tr>
<td>Some college or vocational school</td>
<td>252 32.4</td>
<td>837 34.7</td>
<td></td>
</tr>
<tr>
<td>Graduate or professional school</td>
<td>72 9.3*</td>
<td>274 11.4</td>
<td></td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never</td>
<td>363 46.7</td>
<td>1,155 47.9</td>
<td></td>
</tr>
<tr>
<td>Former</td>
<td>316 40.6</td>
<td>990 41.0</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>99 12.7</td>
<td>268 11.1</td>
<td></td>
</tr>
<tr>
<td>Body mass indexd</td>
<td>27.6 (5.0)*** 26.6 (4.6)***</td>
<td>25.7 (4.2)</td>
<td></td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>138.9 (22.5)***</td>
<td>135.8 (20.8)</td>
<td></td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>70.8 (11.3)***</td>
<td>71.0 (11.1)</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diagnosed</td>
<td>123 16.1</td>
<td>287 12.0***</td>
<td></td>
</tr>
<tr>
<td>Borderline</td>
<td>98 12.8</td>
<td>230 9.6</td>
<td></td>
</tr>
<tr>
<td>No diabetes</td>
<td>542 71.0</td>
<td>1,867 78.3*</td>
<td></td>
</tr>
<tr>
<td>Self-reported hypertension</td>
<td>390 50.2***</td>
<td>908 37.6</td>
<td></td>
</tr>
<tr>
<td>C-reactive protein, mg/L</td>
<td>7.3 (13.6)***</td>
<td>4.9 (8.4)*</td>
<td></td>
</tr>
<tr>
<td>Depressive symptoms (CES-D score ≥16)</td>
<td>37 4.8</td>
<td>99 4.1</td>
<td></td>
</tr>
<tr>
<td>APOE 4 allele carrier</td>
<td>159 22.5*</td>
<td>567 25.5</td>
<td></td>
</tr>
<tr>
<td>3MS Examination score</td>
<td>88.8 (10.5)***</td>
<td>91.0 (8.9)</td>
<td></td>
</tr>
<tr>
<td>DSST score</td>
<td>35.8 (14.0)***</td>
<td>40.2 (13.3)</td>
<td></td>
</tr>
<tr>
<td>Cognitive impairment (3MS Examination score &lt;80)</td>
<td>104 13.4**</td>
<td>96 8.1</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: APOE, apolipoprotein E; CES-D, Center for Epidemiologic Studies Depression Scale; DSST, Digit Symbol Substitution Test; eGFR_{cys}, cystatin C–based estimated glomerular filtration rate; GED, General Education Development; 3MS, Modified Mini-Mental State.

* P < 0.05; ** P < 0.01; *** P < 0.001.

a eGFR_{cys} is measured in mL/minute/1.73 m².
b eGFR_{cys} ≥90 mL/minute/1.73 m² was considered the reference group.
c P values based on pairwise χ² tests for categorical variables and Student’s t tests for continuous variables.
d Weight (kg)/height (m)².
Table 2. Cross-Sectional Association of Kidney Function With Mean Differencea in Cognitive Function at Baseline, Cardiovascular Health Study, 1992–1993

<table>
<thead>
<tr>
<th>Cognitive Function Test, by Model</th>
<th>Subjects With eGFRcys 60–89.9b</th>
<th>Subjects With eGFRcys &lt;60b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean Difference 95% CI</td>
<td>Mean Difference 95% CI</td>
</tr>
<tr>
<td>3MS Examination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Model 1c</td>
<td>0.03 (−0.75, 0.80)</td>
<td>−2.15*** (−3.09, −1.21)</td>
</tr>
<tr>
<td>Model 2d</td>
<td>−0.31 (−0.98, 0.36)</td>
<td>−0.78 (−1.65, 0.09)</td>
</tr>
<tr>
<td>DSST</td>
<td>−1.10 (−2.24, 0.05)</td>
<td>−5.51*** (−6.92, −4.11)</td>
</tr>
<tr>
<td>Model 2d</td>
<td>−0.72 (−1.71, 0.26)</td>
<td>−1.63* (−2.90, −0.36)</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; DSST, Digit Symbol Substitution Test; eGFRcys, cystatin C–based estimated glomerular filtration rate; 3MS, Modified Mini-Mental State.
* P < 0.05; ***P < 0.001.
† Reference group is subjects with eGFRcys of ≥90.
‡ eGFRcys is measured in mL/minute/1.73 m².
§ Unadjusted model.
¶ Adjusted for the following confounders: eGFRcys × year, age, sex, race, education, smoking, body mass index (weight (kg)/height (m)²), diabetes, history of hypertension, C-reactive protein, apolipoprotein E genotype, and depression symptoms.

Higher eGFRcys was associated with life-years of follow-up, and this association remained after adjustment for confounders and hypothesized mediators (Table 4). Participants with eGFRcys of less than 60 had a lower average number of life-years compared to those with eGFRcys of 90 or more (mean difference = −3.05, 95% confidence interval (CI): −3.47, −2.63). Participants with eGFRcys of less than 60 also had fewer CIFLYs compared to those with eGFRcys of 90 or more (mean change in CIFLYs = −0.44, 95% CI: −0.62, −0.26). The association between eGFRcys and CIFLYs was of greater magnitude compared to the association with life-years for all comparisons; in the fully adjusted models, the estimate for CIFLYs was 26% greater (−0.44 vs. −0.35) than the estimate for life-years (Table 4).

A sensitivity analysis that included participants with a history of prevalent clinical cardiovascular disease had similar results compared with the main analysis (fully adjusted estimates for mean change in 3MS Examination score per year were −0.17 (95% CI: −0.27, −0.06) for those with eGFRcys of 60–89.9 vs. those with eGFRcys of ≥90 and −0.58 (95% CI: −0.70, −0.45) for those with eGFRcys of <60 vs. those with eGFRcys of ≥90).

Another sensitivity analysis that included time-dependent hypertension status instead of hypertension status at baseline found similar results (mean changes in 3MS Examination...
score per year were \(-0.13\) (95% CI: \(-0.23, -0.03\)) for those with eGFR\(_{\text{cys}}\) of 60–89.9 vs. those with eGFR\(_{\text{cys}}\) \(\geq 90\) and \(-0.52\) (95% CI: \(-0.65, -0.39\)) for those with eGFR\(_{\text{cys}}\) <60 vs. those with eGFR\(_{\text{cys}}\) \(\geq 90\). A sensitivity analysis that examined the association between eGFR\(_{\text{cys}}\) and 3MS Examination score without imputation found similar results (mean changes in 3MS Examination score per year of \(-0.14\) (95% CI: \(-0.25, -0.04\)) for those with eGFR\(_{\text{cys}}\) of 60–89.9 vs. those with eGFR\(_{\text{cys}}\) \(\geq 90\) and \(-0.55\) (95% CI: \(-0.68, -0.42\)) for those with eGFR\(_{\text{cys}}\) <60 vs. those with eGFR\(_{\text{cys}}\) \(\geq 90\)). We found a strong correlation between eGFR\(_{\text{cys}}\) and eGFR\(_{\text{creatinine}}\) in our study population (Pearson’s correlation coefficient = 0.69). A sensitivity analysis using eGFR\(_{\text{creatinine}}\) failed to find a statistically significant difference in average decrease in 3MS Examination score per year between participants with eGFR of 60–89.9 versus those with eGFR \(\geq 90\) (mean change in 3MS Examination score per year = \(-0.05\), 95% CI: \(-0.08, 0.18\)); however, it remained statistically significant when comparing those with eGFR\(_{\text{creatinine}}\) of less than 60 versus those with eGFR\(_{\text{creatinine}}\) of 90 or more (mean change in 3MS Examination score per year = \(-0.33\), 95% CI: \(-0.48, -0.18\)). Finally, a sensitivity analysis was performed to examine the impact of the remaining 3MS Examination score missingness. Using the deletion/substitution/addition algorithm, we estimated the missing function as the following:

\[
\log \left[ \frac{p(\text{not missing 3 MS Examination score})}{1 - p(\text{not missing 3 MS Examination score})} \right] = 0.506 - 0.457 \times \text{cystatin C} + 1.166 \times \text{heart failure} + 0.037 \times \text{prior 3 MS Examination score}. 
\]

Using the inverse probability of censoring weights, we found that the longitudinal association was similar and remained significant in the fully adjusted model (mean changes in 3MS Examination score per year were \(-0.17\) (95% CI: \(-0.30, -0.05\)) for those with eGFR\(_{\text{cys}}\) of 60–89.9 vs. those with eGFR\(_{\text{cys}}\) \(\geq 90\) and \(-0.58\) (95% CI: \(-0.77, -0.39\)) for those with eGFR\(_{\text{cys}}\) <60 vs. those with eGFR\(_{\text{cys}}\) \(\geq 90\)).

**DISCUSSION**

In a community-dwelling sample of older adults, cystatin C–based kidney function was associated with both the level and change in cognitive function over 6 years of follow-up. The longitudinal association was robust to adjustment for confounders and hypothesized mediators, including demographic characteristics, risk factors, and incident cardiovascular disease and heart failure events; participants with worse baseline kidney function had a steeper decline in predicted cognitive function over the study period. Reduced kidney function was also associated with fewer CIFLYs.

Our findings are consistent with those of prior studies that found an association between kidney function and cognitive

function. Several studies have found an association between eGFR_{\text{creatinine}} and incident cognitive impairment or dementia (12, 14, 33); however, other studies have reported conflicting results (10, 15, 34). A study from the Rush Memory and Aging Project, which investigated the association between eGFR_{\text{creatinine}} and decline in cognitive function, found a statistically significant association over 5 years of follow-up (8). Similarly, another study found that change in eGFR_{\text{creatinine}} was significantly associated with change in cognitive function over 5 years (9). Both of these studies found this association across multiple domains of cognitive function, including global cognition, working memory, and abstract reasoning, and they found that this association persisted despite controlling for cardiovascular risk factors and events, similar to the results of our study. However, unlike our study, these studies used serum creatinine levels to estimate kidney function. We found that using eGFR_{\text{creatinine}} as the predictor of interest instead of eGFR_{\text{cys}} decreased the effect size of the association and failed to demonstrate a difference in cognitive decline between persons with eGFR_{\text{creatinine}} of 60–89.9 and those with eGFR_{\text{creatinine}} of 90 or more.

One study that used cystatin C to estimate kidney function found that, among participants in the Health, Aging, and Body Composition cohort, a population of well-functioning older adults (including both black and white subjects), those with higher cystatin C at baseline had a greater likelihood of developing cognitive impairment over the 7-year study period (for persons with cystatin C >1.25 mg/L vs. persons with cystatin C <1.0 mg/L, odds ratio = 1.92, 95% CI: 1.37, 2.69) (21). Our study confirmed the association between cystatin C–based kidney function in a community-based cohort and demonstrated that this association was robust against adjustment for intermediate cardiovascular events. Additionally, the present study accounted for the impact of kidney function on death and found that persons with eGFR_{\text{cys}} of less than 60 had an average of 0.44 fewer years of cognitively intact life compared with persons with eGFR_{\text{cys}} of 90 or more over 6 years, even after accounting for potential confounders and mediating events. We did not find a statistically significant difference in life-years or CIFLYs for persons with eGFR_{\text{cys}} of 60–89.9, a group that has been described as having “preclinical kidney disease” (3), compared with persons with eGFR_{\text{cys}} of 90 or more.

It has been previously suggested that the mechanisms underlying the association between kidney function and cognitive function may be inflammation and increasing cardiovascular events resulting from chronic kidney disease (35). Our study demonstrates that the association between cystatin C–based kidney function and cognitive function is independent of inflammation, measured by C-reactive protein, as well as intermediate cardiovascular events, including myocardial infarction, stroke, and congestive heart failure. It is possible that changes in brain function due to subclinical or unmeasured ischemic disease may mediate the association between kidney function and cognitive function. Additionally, kidney function is an excellent indicator of vascular aging, reflecting a lifetime of exposure to hypertension, diabetes, and other vascular stressors. It is possible that the association is not caused directly by kidney function, but rather that kidney function is a marker for vascular aging, which is inversely related to cognitive function in older adults.

There are several limitations to this study. First, the mechanism for this association is still unclear; therefore, a causal link between kidney function and cognitive function in older adults is difficult to establish. Second, there was a limited length of follow-up, which may have decreased our ability to describe this association. Third, we did not have a direct measure of glomerular filtration rate; this measure is invasive, time-consuming, and difficult to obtain in a large-scale study of older adults. Finally, lack of data on urinary albumin may be a limitation because some evidence suggests it may be more strongly associated with stroke and abnormalities detected by magnetic resonance imaging (36).

In summary, kidney function is associated with change in cognitive function over time in older adults. This indicates that people with reduced kidney function are at higher risk for declines in cognitive health. Earlier interventions for people with declining kidney function may help preserve cognitive function and deter its devastating effects on quality of life and independence.

ACKNOWLEDGMENTS

Author affiliations: School of Biological and Population Health Sciences, Oregon State University, Corvallis, Oregon (Brendan Darsie, Michelle C. Odden); Division of General Internal Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California (Michael G. Shlipak); Division of General Internal Medicine, Department of Medicine, University of California, San Francisco, California (Michael G. Shlipak); Department of Epidemiology and Biostatistics, University of California, San Francisco, California (Michael G. Shlipak); Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts (Mark J. Sarnak); Kidney Research Group, University of Washington, Seattle, Washington (Ronit Katz); Department of Epidemiology, University of Washington, Seattle, Washington (Annette L. Fitzpatrick); and Department of Global Health, University of Washington, Seattle, Washington (Annette L. Fitzpatrick).

This research was supported by the National Heart, Lung, and Blood Institute (contracts HHSN26820120036C, HHSN 268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086, and grant HL080295), with additional contributions from the National Institute of Neurological Disorders and Stroke. Additional support was provided by the National Institute on Aging (grants R01AG023629 and R01AG027002). A full list of principal Cardiovascular Health Study investigators and institutions can be found at http://www.chs-nhlbi.org/PI.htm. M.C.O. is supported by the American Heart Association Western States Affiliate (grant 11CRP7210088) and the National Institute on Aging (grant K01AG039387).

Conflict of interest: none declared.

REFERENCES


